Education
The Ohio State University, Columbus, OH BS 1972 Microbiology
The Ohio State University, Columbus, OH MS 1974 Micro/Pathology
The Ohio State University, Columbus, OH PhD 1977 Immunology
Michigan Cancer Foundation, Detroit, MI 1977-1979Postdoctoral Training

Positions and Honors

Professional Experience
1979 - 1981 Senior Research Associate, Michigan Cancer Foundation, Detroit, MI
1981 - 1985 Scientist, AMC Cancer Research Center, Denver, CO
1985 - 1988 Senior Scientist, AMC Cancer Research Center
1988 - 1989 Adjunct Assistant Professor, Dept of Medicine, Univ. of Colorado School of Medicine, Denver, CO
1988 - 1989 Chief, Laboratory of Experimental Hematology, AMC Cancer Research Center
1989 - 1993 Associate Professor, Dept of Pathology, Univ. of Pittsburgh School of Medicine, Pittsburgh, PA
1989 - 1994 Associate Professor, Dept of Otolaryngology, Univ. of Pittsburgh School of Medicine (tenure conferred 1992)
1993 - 1994 Associate Professor, Dept of Pharmacology, Univ. of Pittsburgh School of Medicine
1995 - 1997 Professor, Depts of Otolaryngology and Pharmacology, Univ. of Pittsburgh School of Medicine
1997 - 2002 Professor, Depts of Pharmacology and Medicine, Univ. of Pittsburgh School of Medicine
2002 - Senior Vice-President, Translational Research, Roswell Park Cancer Institute, Buffalo, NY
2002 - Member, Dept of Pharmacology and Therapeutics, Roswell Park Cancer Institute
2002- Professor, Dept of Pharmaceutical Sciences, University at Buffalo, NY
Other Appointments (selected)
1987 - 1989 Full Member, University of Colorado Comprehensive Cancer Center
1989 - 2002 Full Member, Pittsburgh Cancer Institute, National Cancer Institute Designated Cancer Center
1990 - 1994 Member, Experimental Therapeutics-2 Study Section, Division of Research Grants, NIH
1990 - 2002 Co-Program Director, Molecular Therapeutics/ Drug Discovery Program, University of Pittsburgh Cancer Institute, NCI designated Cancer Center
1994 - Member, NIH Reviewers Reserve
1995 - 2000 Member, Experimental Therapeutics-2 Study Section, Division of Research Grants, NIH
1998 - 2002 Deputy Director for Basic Research, University of Pittsburgh Cancer Institute, NCI designated Cancer Center
2000 - 2004 Member, NCI Initial Review Group, Subcommittee A - Cancer Centers (Parent Committee) NIH
2003 - Member, Scientific Advisory Committee, Ralph Wilson Medical Research Foundation

Selected Peer-Reviewed Publications

Johnson CS, Hershberger PA, Trump DL. 1,25 Dihydroxycholecalciferol (calcitriol) as an anticancer agent: Preclinical Studies. Vitamin D Endocrine System, Norman AW, Bouillon R, Thomasset M, ed. University of California Printing, Riverside, CA pp461-468 (2000)

Hershberger PA, Yu WD, Modzelewski RA, Rueger, Johnson CS, Trump DL. Calcitriol enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clin Cancer Res 7, 1043-1051 (2001)

McGuire TF, Trump DL, Johnson CS. Vitamin D3-induced apoptosis of murine squamous cell carcinoma cells selective inductions of caspase-dependent MEK cleavage and up-regulation of MEKK-1*. J Biol Chem 276, 26365 - 26373 (2001)

Bernardi RJ, Trump DL, Yu WD, McGuire TF, Hershberger PA, Johnson CS. Combination of 1,25-dihydroxyvitamin D3 with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clin Cancer Res 7, 4165-4173 (2001)

Johnson CS, Hershberger PA, Bernardi RJ, McGuire TF, Trump DL. Vitamin D receptor: A potential target for intervention. Urology 60(1):123-130 (2002)
Ahmed S, Johnson CS, Rueger RM, Trump DL. Calcitriol (1,25 dihydroxycholecalciferol) potentiates activity of mitoxantrone/dexamethasone in an androgen independent prostate cancer model. J Urol 168(2), 756-761 (2002)

Fakih M, Johnson CS, Trump DL. Glucocorticoids and the Treatment of Prostate Cancer: A Review of Pre-clinical and Clinical Efficacy Data. Urology 60, 553-561 (2002)

Bernardi RJ,.Modzelewski RA, Trump DL, Johnson CS. Anti-proliferative effects of 1?, 25-dihydroxvitamin D3 and vitamin D analogs on normal and tumor-derived murine endothelial cells. Endocrinology 143, 2508-2514 (2002)

Muindi JR, Peng Y, Potter DM, Hershberger PA, Tauch JS, Capozzoli MJ, Egorin MJ, Johnson CS, Trump DL. Pharmacokinetics of high dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Cancer Pharm Therap 72(6), 648-659 (2002) Hershberger PA, McGuire TF, Yu W-D, Zuhowski EG, Egorin MJ, Trump DL, Johnson CS. Cisplatin potentiates 1,2-dihydroxyvitamin D3-induced apoptosis. Mol Cancer Ther. 1, 821-829 (2002)

Johnson CS, Hershberger PA, Trump DL. Vitamin D-related therapies in prostate cancer. Cancer Metast. Rev. 21, 147-158 (2002)

Logan TF, Jadali F, Egorin MJ, Mintun M, Sashin D, Gooding WE, Choi Y, Bishop H, Trump DL, Gardner D, Kirkwood J, Vlock D, Johnson CS. Decreased tumor blood flow as measured by position emission tomography in cancer patients treated with IL-1 and carboplatin on a phase I trial. Cancer Chemother Pharmacol 50(6), 433-444 (2002)

Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GC, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, McLeod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 60, 1-6 (2002)

Matin K, Egorin MJ, Ballesteros MF, Smith DC, Lembersky B, Day RS, Johnson CS, Trump DL. Phase I pharmacokinetic study of vinblastine and high dose megesterol acetate. Cancer Chemother Pharmacol 50(3), 179-185 (2002)

Xiao D, Srivastava SK, Lew K, Zeng Y, Kokkinakis DM, Hershberger P, Johnson CS, Trump DL, Singh SV. Allyl Isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of human prostate cancer cells in culture and in vivo in nude mice by inducing apoptosis and causing G2/M arrest. Carcinogenesis 24(5), 891-897 (2003)

Muindi JR, Wilson JW, Peng Y, Cappozolli MJ, Johnson CS, Trump DL. A limited sampling method for the estimation of serum calcitriol area under the curve in cancer patients. J Clin Pharm 43, 894-900 (2003)

S.K. Srivastava, D. Xiao, K.L. Lew, P. Hershberger, D.M. Kokkinakis, C.S. Johnson, D.L. Trump, and S.V. Singh. Allyl isothiocyanate, a constituent of cruciferous vegetables, inhibits growth of PC-3 human prostate cancer xenografts in vivo. Carcinogenesis 24(10), 1665-1670 (2003).

Eto M, Bennouna J, Hunter OC, Hershberger PA, Kanto T, Johnson CS, Lotze MT, Amoscato AA. C16 ceramide Accumulates following androgen ablation in LNCaP Prostate Cancer Cells. Prostate 57:66-79 (2003).

Muindi JR, Modzelewski RA, Peng Y, Trump DL, Johnson CS. Pharmacokinetics of 1a,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology 66, 62-66 (2004)

D. Xiao, C.S. Johnson, D.L. Trump, and S.V. Singh. Proteasome-mediated Degradation of Cell Division Cycle 25C and Cyclin-dependent Kinase 1 in Phenethyl Isothiocyanate-induced G2/M Phase Cell Cycle Arrest in PC-3 Human Prostate Cancer Cells. Mol Cancer Ther 3(5), 567-575 (2004).

Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu W-D, Johnson CS. Anti-tumor activity of calcitriol: pre-clinical and clinical studies. Steroid Biochem Mol Biol 89-90:519-526 (2004).

Xiao D, Choi SA, Johnson DE, Vogel V, Johnson CS, Trump DL, Lee Y, Singh SV. Diallyl trisulfide-induced apoptosis in human prostate cancer cells is mediated by activation of c-Jun N-terminal kinase and extra-cellular-signal ergulated kinase-mediated phosphorylation of Bcl-2. Oncogene 23(33), 5594-5606 (2004).

OTHER SUPPORT
ACTIVE:
Title: Anti-tumor mechanisms & therapeutic effects of vitamin D
Principal Investigator: Candace S. Johnson; Co-Principal Investigator: Donald L. Trump
Agency: NCI $250,000
Type: R01-CA-67267-10 Period: 03/01/03 - 02/28/08 Percent Effort: 30% Overlap: None
The overall goal of this study is to examine the mechanisms of vitamin D anti-tumor activity either alone or in combination with platinum agents and to determine whether these effects can be exploited therapeutically.

Title: Glucocorticoids and vitamin D: modulation of anti-tumor effects
Principal Investigator: Candace S. Johnson; Co-Principal Investigator: Donald L. Trump
Agency: NCI $221,292
Type: R01-CA-85142-05 Period: 02/01/00 - 07/31/05 Percent Effort: 25% Overlap: None
The major goal of this study is to conduct basic and clinical research using various glucocorticoids and vitamin D to modulate anti-tumor effects.

Title: Vitamin D in prostate cancer: tumor vasculature effects
Principal Investigator: Donald L. Trump; Co-Principal Investigator: Candace S. Johnson
Agency: NCI $250,000 Type: RO1-CA-95045-01 Period: 09/01/02 - 08/31/07 Percent Effort: 15% Overlap: None
The major goal of this study is to examine the effect of calcitriol both pre-clinically and clinically on tumor vasculature.

Title: Vitamin D analogs for chemoprevention of prostate cancer
Principal Investigator: Barbara A. Foster; Co-Investigator: Candace S. Johnson
Agency: NCI $250,000
Type: R01-CA-95367-01 Period: 09/01/02 - 08/31/07 Percent Effort: 5% Overlap: None
The major goal of this study is to utilize the TRAMP model of prostate cancer to examine the chemopreventative effects of vitamin D and its analogues.

Title: Cancer Center Support Grant
Principal Investigator: David C. Hohn; Director of Translational Research: Candace S. Johnson
Agency: NCI $2,002,499
Type: P30 CA016056-27 Period: 08/01/03 - 04/30/08 Percent Effort: 10% Overlap: None
Roswell Park Cancer Institute's Cancer Center Support Grant (CCSG) includes five programs and 15 Cores. Support is provided for leadership, developmental funds, planning and evaluation and administration.

PENDING:

Title: Glucocorticoids and vitamin D: modulation of anti-tumor effects (Renewal)
Principal Investigator: Candace S. Johnson; Co-Principal Investigator: Donald L. Trump
Agency: NCI $250,000
Type: R01-CA-85142-05 Period: 08/01/04 - 07/31/09 Percent Effort: 25%
Same as above.

Title: Postdoctoral Research Training in Surgical Oncology
Principal Investigator: William G. Kraybill; Co-Principal Investigator: Candace S. Johnson
Agency: NCI $233,240
Type: T32 Period: 07/01/04 - 06/30/09 Percent Effort: 10% Overlap: None
The overall objective of the program is to train clinicians from surgical oncology to develop skills and expertise in basic science and translational research.